Ten adult patients with human immunodeficiency virus (HIVJ-associated malignancies (five with lymphoma and five with Kaposi's Sarcoma) were treated with a daily subcutaneous injection of interleukin-2 (IL-2) for 90 consecutive days in a phase I dose-escalation study. Seven patients had absolute CD4 counts below 200/mm3 at the time malignancy was diagnosed. Each lymphoma patient had obtained a complete or partial remission with standard chemotherapy before initiating IL-2. The daily dose of IL-2 did not change during the 90-day course of therapy. Seventeen courses of IL-2 therapy were completed at doses ranging from 0.4 x lo6 U/m2/d t o 1.2 x 10" U/m2/d without significant (grade 111) toxicity. Two of two patients experienced grade 111 toxicity within 21 days of initiating IL-2 at a dose of 1.4 x IO* U/m2/d, but both patients subsequently completed 90 days of therapy a t the maximum tolerated dose (MTD) of 1.2 x 10' U/mz/d. Although there were no significant increases or decreases in T-cell subsets at any dose level, there was an increase in absolute natural killer INK) cell number at the three highest doses of IL-2 (mean percent increase 247; 95% confidence interval, 124 t o 369) that was statistically significant (Wil-
NFECTION WITH the human immunodeficiency virus (HIV) results in progressive decline in T-helper cell
number and function that causes humoral and cellular immune dysfunction.' This in turn leads to an increased incidence of opportunistic infections and malignancies in this patient population. Specifically, Kaposi's Sarcoma (KS) and non-Hodgkin's lymphoma (NHL) have a greater than 700-fold and 70-fold higher incidence in HIV+ patients, respectively, when compared with age-matched noninfected controls.' Both are associated with a poor o~t c o m e .~.~ Cytokines are thought to play an important role in pathogenesis of HIV as well as the immunologic decline that favors the emergence of malignancy and opportunistic infect i~n .~
The polarization of the TH, or cell mediated immune response versus the TH2 or humoral host response is likely to contribute to this susceptibility.6 Interleukin-2 (IL-2) is a TH, cytokine that is critical for the T-cell response after antigen activation.' IL-2 has also been shown to prevent programmed cell death or apoptosis of HIV infected T cells in vitro. 8 We have previously shown that low-dose IL-2 can be administered subcutaneously for a prolonged period of time in patients with cancer resulting in immune modulation without significant clinical toxicity.' In the present study we have administered a daily, subcutaneous low dose of IL-2 to patients with HIV-associated malignancy for 90 consecutive days to assess for toxicity, pharmacokinetics, and immune modulation. coxon one-sample signed rank test, P = .015). One patient developed an anti-IL-2 antibody titer that correlated with minimal NK cell expansion in vitro and in vivo. An increase in eosinophils was noted during 9 of 17 courses of IL-2 therapy without correlation t o IL-2 dose, prior course of IL-2, or NK cell expansion. At the MTD, there was no consistent increase in the plasma HIV RNA level over time. Three of 10 patients had progressive disease while on study. During 50 months of IL-2 therapy, no patient was treated for an opportunistic infection. We conclude that daily low dose subcutaneous IL-2 can be self-administered safely with good compliance for prolonged periods of time t o patients with HIV-associated malignancies, including those with profound immune deficiency. The majority of patients show selective expansion of innate immune effectors, ie, NK cells and/or eosinophils, in the absence of significant clinical toxicity or increased viral burden. These results suggest that low-dose IL-2 therapy should be studied further in phase II clinical trials for evidence of activity against malignancy and opportunistic infection in this patient population. tion as well as a tissue diagnosis of malignancy. Lymphoma patients were required to have achieved either a complete response (CR) or a partial response (PR) for a minimum of 1 month following a standard chemotherapy regimen. Patients with KS were eligible to begin therapy after diagnosis, with or without a history of prior therapy. All evaluable patients were on anti-retroviral therapy at time of entry and were not permitted to change their anti-retroviral therapy while receiving IL-2. Patients with malignant central nervous system (CNS) disease were excluded, and patients who were noncompliant with regard to daily self administration of IL-2 were removed from study. All patients signed an informed consent approved by the Institutional Review Board before the initiation of their treatment.
I PATIENTS AND METHODS

Patient
Drug preparation and study design. Human recombinant IL-2 (Proleukin) was supplied by Chiron Corp (Emeryville, CA; specific activity = 1.8 X IO' IU/mg) as a lyophilized cake in 5-mL vials containing 1 mg of protein. Each vial was reconstituted with 1.2 mL of sterile water. Each vial was further diluted using sterile 5% dextrose with 0.1 % human albumin, USP (Armour Pharmaceutical CO, Kankakee, IL). Three-milliliter syringes with an attached 27-gauge needle suitable for subcutaneous injection were each filled with a total volume of 1 mL containing the prescribed dose of IL-2 and labeled as such. Stability and sterility testing had shown 100% bioactivity and no evidence of bacterial contamination by culture when Proleukin was reconstituted in this fashion and kept refrigerated at 2°C to 8°C for 14 days. Patients were instructed on subcutaneous self administration and did so on an outpatient daily basis, rotating between seven designated sites of injection, each specified for a day of the week. Patients were given a 13-day supply of prefilled labeled syringes. On the 14th day, subcutaneous injection of IL-2 was performed at Roswell Park Cancer Institute so that studies described below could be performed.
The daily dose of IL-2 administered to the patient did not change during the 90-day course of therapy. For a course of IL-2 to be considered evaluable, a patient had to receive 45 consecutive days of the daily specified dose of IL-2. Patients who completed 90 days of the therapy without greater than grade I1 toxicities (Common Toxicity Criteria [CTC]) were eligible to re-enter the study at a higher dose after 3 weeks off of 1L-2. Patients who suffered grade 111 or IV toxicities were eligible to receive a reduced dose as specified below. Dose escalations were undertaken when three consecutive entrants completed 2 4 5 days of therapy with sgrade 11 toxicity. The maximum tolerated dose (MTD) was defined as one dose level below the dose level in which 2 of 3 patients experienced >grade 111 toxicity.
Patient evaluation. Once enrolled on study patients were evaluated every 2 weeks with history, physical exam, and blood tests for routine chemistry, complete blood count (CBC), pharmacokinetics and additional laboratory studies described below. Responses were defined as follows: continued complete response (CCR) = no evidence for clinically detectable disease; PR = greater than 50% reduction in the sum of the products of the perpendicular diameters of marker lesions, with no progression of existing lesions or development of new lesions; stable disease (SD) = less than 25% increase or less than a 50% decrease in marker lesions with no progression in other sites or development of new lesions; progressive disease (PD) = greater than 25% increase in marker lesions or the appearance of new lesions. A documented response had to last at least 4 weeks determined by two successive evaluations. Pharmacokinetics and cytokine determination. Plasma IL-2 concentrations were determined from blood samples collected before injection and at 1, 4, and 6 hours after subcutaneous injection of IL-2 in all patients. Measurements were determined by ELISA purchased from Advanced Magnetics (Cambridge, MA) following the manufacturer's recommendations. Human tumor necrosis factor-cu (TNF-a), granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-10 levels were measured in patients treated at the MTD by ELISA (R & D Systems, Minneapolis, MN), following the manufacturer's recommendations.
HIV plasma quantitation. Quantitation of HIV in plasma samples was performed in patients treated at the MTD using two separate methods. For each, plasma was collected and immediately placed on ice and subsequently frozen at -70°C until use in the assays. The first method used an RNA directed polymerase chain reaction (PCR). All work was performed on ice or at 4°C. Two milliliters of plasma was thawed and spun at 500 g for 5 minutes. The supernatant was removed and centrifuged at 10,500g for 45 minutes. The pellet was resuspended in 200 pL of RNA lysis buffer (0.15 m o m NaC1, 1.5 mmol/L MgCl?, 10 mmol/L Tris [pH 7.61, 1.5 mmoVL dithiothreitol, and 300 U RNAsin), and placed on ice for 5 minutes. Two hundred microliters of buffer (140 mmol/L NaCI, 1.5 mmol/L MgC12, 10 mmoVL Tris [pH 8.01, 1% NP-40, 1.0 p g of proteinase K, and I5 pg of tRNA) was then added to the sample for 5 minutes.
The nucleic acid was extracted by the addition of 800 pL of chloroform:phenol ( I : 1, vol:vol). After 10 minutes the phases were separated by centrifugation (10,500g) for 2 minutes. The sample was divided into two and the nucleic acid was precipitated from the aqueous layer using 40 pL of 3 N Na acetate and 1.5 mL of 95% ethanol (-20°C) and subsequent centrifugation at 10,500g for 15 minutes. Each of the nucleic acid pellets was resuspended in 11.5 pL of ddH20. Six units of DNase and I O U of RNasin were added and the samples were incubated at 37°C for 1 hour. The sample was then incubated at 95°C for I O minutes. One of the replicates was then subjected to quantitative conventional PCR and the other to RNA PCR as previously described using HIV-I gag primer pair SK38/SK39.Io." Dilutions of cell line 8E5, which contains one defective copy of HIV-I , was used as DNA standard, whereas synthetic HIV-1 gag RNA was used as the RNA standard. The second method used for HIV RNA quantitation was the branch-chain DNA assay and was performed on identical samples by a different laboratory as previously described.'?
Anti-!L-2 antibody. Sera were prepared from patients' blood and assayed by ELISA for anti-IL-2 antibody (both IgM and IgG) before and during each course of therapy of 1L-2, and were determined using the methods of Scharenberg et al." IL-2 was distributed to 96-well microtiter plates ( I I million Ulwell). After 18 hours at 25°C the wells were rinsed with Tris-HCI-buffered saline (TBS) (pH 8.5) and incubated with 300 pL bovine serum albumin (10 mg/ mL in phosphate-buffered saline) for 1 hour at 37°C. After washing with TBS, 95 pL of test serum or sera from positive and negative controls was added for 2 hours at 37°C. The wells were then washed three times with TBS-0.5% Tween 20 followed by the addition of SO pL horseradish peroxidase-goat-antihuman IgG or 1gM (Zymed Laboratories, San Francisco, CA). After a l-hour incubation at 37OC. the wells were washed three times with TBS-Tween 20 (pH 8.0) and twice with distilled water. Substrate (ortho-phenylenediamine) was then added, and after 30 to 60 minutes at 37°C the wells were read in a spectrophotometer (410 nm).
All sera were screened using duplicate 16-fold dilutions, after which those sera with absorbances greater than 0.5 were retested using threefold serial dilutions. The ELISA titer was defined as the product of absorbance and dilution factor, when the absorbance was between 0.1 and 0.5. ELISA titers exceeding IO were considered positive. Sera of healthy control donors showed ELISA titers between l and 4, whereas positive control serum pooled from four positive donors, had an ELISA titer between 60 and 70.
CD56""Rh' NK cell proliferation assay. The assay was performed on CD56b"gh' NK cells from a healthy donor that were sorted to 97% purity as previously de~cribed.'~ In place of 10% commercial human AB serum, the medium contained 10% serum from designated donors as described below. All sera were added 15 minutes before the addition of 20 pmol/L IL-2.
Immunojuorescence and phenotyping. The procedures used in these studies have been described in detail elsewhere." The combinations of directly conjugated monoclonal antibodies used were HTC-CD3, PE-CD4, TRI-CD8; and FITC-CD16, PE-CD56, and TRI-CD3 (Becton Dickinson, San Jose, CA).
Statistics. 
RESULTS
Patient characteristics.
Eleven patients enrolled onto the study, and 21 courses of IL-2 therapy were initiated. Seventeen courses were subsequently found to be evaluable by the established criterion. Two courses that were initiated were deemed nonevaluable because of poor compliance unrelated to toxicity, and two courses were nonevaluable because of early toxicity. Table 1 describes the clinical features of the 10 patients who completed 17 evaluable courses of therapy. All patients were men with a median age of 37, and each had a Karnofsky performance status of 80. All but one patient had a diagnosis of HIV before the diagnosis of malignancy. Every patient was on anti-retroviral therapy before the initiation of IL-2. CD4 counts listed in Table l were obtained at the time that malignancy was diagnosed, and show that 7 of the 10 patients had absolute CD4 counts below 200/mm3. Four patients were diagnosed with NHL and one had Hodgkin's disease. None of the lymphoma patients had bone marrow or CNS involvement. At the time that IL-2 was initiated, 3 patients with lymphoma (1 with Hodgkin's disease and 2 with non-Hodgkin's Disease) were in CR after standard chemotherapy, whereas the remaining two patients with NHL had SD. Five patients were diagnosed with KS, but only one had radiographic evidence of visceral involvement. Three of the five patients were started on IL-2 therapy within 2 months of being diagnosed with KS, one patient had longstanding SD, and one patient achieved SD status 20 months after diagnosis.
The doses of IL-2 and the number of courses administered, as well as the mean length of time patients were on study, are listed in Table 2 . Ten patients received 17 evaluable courses of IL-2 at the first four dose levels. All but one evaluable course continued for 90 consecutive days. One patient (unique patient number [UPN] 9) treated at a daily dose of 0.9 X lo6 U/m2/d had to be removed from the study after 56 days because of limited access to transportation. The two patients treated at a dose of 1.4 X IO6 U/m2/d both experienced severe constitutional symptoms shortly after initiating treatment as described below and were discontinued at that dose. Toxicities. A listing of the clinical toxicities encountered by all patients enrolled on study is shown in Table 3 . At the first four dose levels all toxicities were mild (sgrade 11) and did not result in discontinuation of therapy or attenuation in dose for any patient. One individual developed a grade I thrombocytopenia (1 16,000/mm3) detected on day 28 which remained at this level throughout therapy. One patient developed transient hyperkalemia and three patients had brief episodes of grade I diarrhea. There were no pulmonary, cardiovascular, or neurologic toxicities experienced by study patients. The most commonly noted side effects were mild flu-like symptoms and local reaction at the site of injection manifested by erythema of 1 to 2 cm in diameter and induration of 0.5 to 1.5 cm. This was usually manifested within 12 hours of injection, peaking at 24 hours, with complete resolution of erythema at 48 to 72 hours and complete resolution of induration at 3 to 5 days postinjection. These local responses did not vary with dose nor days elapsed on study.
The first two individuals entered at the dose level of 1.4 X lo6 U/m2/d experienced grade 111 toxicity of fatigue (one patient) and fevers (both patients) at day 10 and day 25 in their courses, respectively. All symptoms resolved within 48 hours of discontinuing the IL-2. These two patients and two additional patients completed a 90-day course of IL-2 at a dose of 1.2 X lo6 U/m2/d and did not experience toxicities greater than grade 11. The MTD was therefore defined at an IL-2 dose of 1.2 X lo6 U/m2/d. QuantiJication of HIV plasma viremia. Plasma samples were obtained from four patients treated at the MTD of 1.2 X IO6 U/mz/d, just before initiation of IL-2 and at weeks 6 and 10 of therapy. Results from the HIV RNA PCR assay are shown in Table 4 and did not show any consistent increase in plasma HIV RNA load over time at this daily subcutaneous dose of IL-2. These results were confirmed on identical samples that were assayed in a different laboratory using the branch chain DNA method (not shown).
IL-2 pharmacokinetics, anti-IL-2 antibodies, and secondary cytokine measurements. Peak plasma concentrations of
IL-2 were noted 4 hours after injection, and were between 10 pmol/L (-2 IU/mL) and 38 pmolk, without a direct correlation to IL-2 dose (Fig 1) . Serum from each patient before initiating therapy with IL-2 and during weeks 10 through 12 was collected and assayed for anti-IL-2 antibodies. Only one patient (UPN 4), treated at 0.4 X lo6 U/m2/d and again at 0.9 X lo6 U/m2/d, had serologic evidence of anti-IL-2 antibodies. At the end of his first course of IL-2 therapy he converted to seropositivity with a titer of 88, and had a subsequent increase to 167 toward the end of his second course of IL-2 therapy. Consistent with this, this patient had a relatively distinct pattern of cellular immune modulation in vivo and in vitro, as discussed below. Plasma from four patients treated at the MTD was also assayed for GM-CSF, TNF-a, and IL-l0 by ELISA, but all levels were below the detection limits of the assays (2.8 pg/mL, 4.4 pg/ mL, and 5.0 pg/mL, respectively; not shown).
Quantitation of peripheral blood cell response. A complete blood count and flow cytometric analysis of peripheral blood lymphocytes were undertaken every 2 weeks while patients were on study. No significant changes were noted in absolute values of neutrophils, monocytes, platelets, or hemoglobin (not shown). However, eosinophils were noted to increase during the first 8 weeks in 9 of 17 evaluable courses of IL-2 therapy. The increase in the absolute number of eosinophils appeared to be independent of the number of eosinophils present before IL-2 as well as the dose or prior administration of IL-2 (Fig 2) . For example, the four patients who achieved the highest serum IL-2 concentrations at the 4-hour time point (Fig l) had inconsistent increases in absolute numbers of eosinophils, ranging between 1.4-and 9.2-fold.
The percent change in the absolute number of CD4' T cells, CD8' T cells, and CD3-CD56' NK cells for 17 evaluable courses of therapy is shown in Fig 3. Although there was no significant increase or decrease in the absolute number of CD4' T cells or CD8+ T cells at any dose of IL-2, there was an increase in the absolute number of NK cells seen in patients who completed therapy at the three highest dose levels (mean percent increase 247; 95% confidence interval, 124 to 369) that was statistically significant (Wilcoxon onesample signed rank test, P = .015). The peak in NK cell expansion occured at a mean of 7.8 weeks. Only one patient (UPN 4) developed a measurable anti-IL-2 antibody titer that reached 167 during his second course of IL-2 at a dose of 0.9 X lo6 U/m2/d. This patient failed to significantly expand his absolute NK cell number in vivo (42%), compared with UPNs l and 3 who also received 0.9 X IO6 U/m2/d of IL-2 and showed a 219% and a 242% increase in absolute NK cell number, respectively (Fig 3) . Furthermore, an in vitro NK cell proliferation assay performed in the presence of picomolar concentrations of IL-2 showed clear evidence of inhibition when culture medium contained 10% serum from UPN 4 compared with 10% sera from other HIV-and HIV+ controls (Fig 4) .
The CD56briBhh' NK subset has high density expression of CD56, normally constitutes 5% to 10% of NK cells and 1% of lymphocytes, and is the only population to constitutively express the high-affinity IL-2 re~eptor.'~ As such, the CD56bngh' NK cell can bind picomolar concentrations of IL-2 that were transiently detected in the sera of most patients treated at the three highest dose levels (Fig 1) . Indeed, within the NK cell population, the increases in the absolute number were most pronounced within the CD56bngh' NK cell subset, as illustrated in Fig 5. Diseuse response. The clinical outcome of the 10 patients who received 17 courses of IL-2 therapy is summarized in Table 5 . Two of the five patients with KS (UPNs 2 and 5) developed new KS lesions on days 87 and 86 of their first course of IL-2 therapy, respectively. UPN 2 died of PD 15 months after discontinuing therapy, and UPN 5 died of overwhelming CMV infection 14 months after discontinuing IL-2 therapy. UPN 6 had KS and completed 1 course of IL-2 therapy and 28 days of a second course, when he became noncompliant for reasons unrelated to toxicity. He remained with SD for 2 months after completion of his first course and died of PD 6 months later. UPN 10 developed PD 1 month after completing IL-2. UPN 4 initiated IL-2 therapy 22 months after being diagnosed with KS, having achieved SD status 2 months before entering the trial. He completed two courses and has remained with SD for 17 months. However, during this time he has received liposome-encapsulated 800 500- 
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100. doxorubicin for stable but disfiguring KS lesions, without further response. UPN 8 had NHL and was in partial remission for 1 month after standard chemotherapy and before IL-2. During the last week of his second course of IL-2 he experienced growth in an axillary lymph node. Interestingly, he had the highest absolute CD4' T-cell count when diagnosed with malignancy (855/mm'), and has been the only patient with lymphoma to show progression on study. Another patient with lymphoma (UPN 7) remained without evidence of disease while receiving IL-2 but died of CNS Toxoplasma gondii 8 months after discontinuing IL-2 therapy. The three remaining patients (2 NHL, I HD), remain alive without recurrence or progression. During 50 months of IL-2 administration delivered in 17 courses to the I O evaluable patients, there were no documented opportunistic infections.
DISCUSSION
With the advent of PCR-based methodologies, it is now clear that the number of cells harboring the HIV genome after infection is several orders of magnitude greater than once perceived, and modest decreases in CD4' T cells during the asymptomatic phase of the infection result from the remarkable regenerative capacity of the immune system in the face of widespread viral dis~emination.'~.'' Gradually, the abundance and activity of the virus leads to the demise of the immune system through aberrant immune activation, depletion of CD4' T cells, and disregulation of cytokine production.'.'.' While the pathogenesis of AIDS is therefore multifactorial and highly complex, attempts to reverse these processes must be made to slow the inevitable progression to profound immunosuppression that leads to fatal opportunistic infections and/or malignant transformation. Such at- The bottom t w o histograms show that in the same patient, the expansion of human NK cells is predominated by the CD3-CD56b"gh' NK subset, which underwent an increase from 1% t o 6% during 11-2 therapy. A lymphocyte gate was used for this analysis.
tempts should be made with careful attention at avoiding further increases in HIV viral load. IL-2 is a lymphocytotrophic hormone that is critical to the hosts' normal cellular and humoral immune response: For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From and whose gene expression has been shown to be profoundly impaired in peripheral blood and lymph node CD4+ T cells early in the course of HIV i n f e~t i o n .~.~. '~. '~ Earlier work from our laboratory had established that the exogenous administration of a daily low dose of IL-2 could prevent Epstein-Barr virus-associated lymphoproliferative disease in the severe combined immune deficient mouse engrafted with human lymphocytes, by augmenting CD8' T cell and NK cell responses in the absence of CD4' cells.'" Therefore, we were interested in investigating the use of cytokine replacement therapy with IL-2 in patients with HIV-associated malignancy.
With this in mind, we have performed a phase I outpatient study administering a daily, subcutaneous low dose of IL-2 to patients with HIV-associated malignancies. A single dose of 1L-2 was self administered for 90 consecutive days by 10 patients who completed 17 courses of therapy. Overall, compliance with this regimen was excellent, with only two courses proving nonevaluable because of poor compliance. Toxicity was mild and limited to reactions at the site of injection, fatigue, and fever that did not require hospitalization. Interestingly, the two patients who experienced grade 111 toxicity of lethargy and/or fever early in their course at a dose of 1.4 X IO6 U/m'/d were able to complete a 90-day course of therapy with only a 14% dose reduction, and did so without any significant clinical toxicity.
At the defined MTD of 1.2 X loh U/m*/d we did not see any consistent increase in the plasma HIV RNA level in each of the four patients treated. In an earlier study, 25 HIV+ patients were treated with significantly higher doses of IL-2 (1 8 million U/d by continuous intravenous infusion for 5 days every 8 weeks).2' Eight of 22 evaluable patients experienced at least a 50% increase in the number of CD4+ cells, yet 14 patients experienced a consistent increase in p24 antigen or in the plasma HIV RNA level, many of which were sustained." Although patients enrolled in the current study failed to show any significant increase in CD4' or CD8' T cells at any dose of IL-2, there were significant increases in CD3-CD56+ NK cells in patients who completed therapy at the three highest doses of IL-2. Within the NK cell population, the CD3-CD56b"ghh' NK subset showed the most profound expansion, consistent with its unique constitutive expression of the high-affinity IL-2 receptor and consequent ability to bind picomolar concentrations of IL-2I4 that were present in the serum of these patients for several hours. A number of patients also showed significant increases in the absolute number of eosinophils as reported for non-HIVinfected cancer patients receiving low-dose IL-2 therapy.2' Thus, it is possible to expand innate immune effector cells, including cytotoxic lymphocytes, in HIV' patients without significant clinical toxicity and without apparent increases in HIV RNA plasma load. Importantly, the majority of these patients were profoundly immunosuppressed with absolute CD4' T-cell counts below 200/mm'.
Innate immunity is antigen-independent and the foundation of host defense against infection and malignant transformation in multicellular organisms. Primary effector cells of innate immunity consist of neutrophils, macrophages, NK cells, mast cells, and eosinophils. These cells and the cytokines they produce have important influence on the development and function of antigen-specific immunity.*' In experimental in vivo systems, NK cells are pivotal in providing interferon-y to monocytes/macrophages for successful eradication of infection by obligate intracellular pathogens such as Toxoplasma gondii and Listeria monocytogene.~.~~ Although the in vivo role of eosinophils still remains to be fully elucidated, they have been shown to function as HLA-DR-dependent, major histocompatibility complex-restricted antigen-presenting cells in stimulating proliferation of human T cells or T-cell clones." Thus, expansion of these effector cells with low-dose IL-2 may ultimately provide assistance in limiting the infectious or malignant complications in severely immunocompromised hosts.
The patients who were entered on this study were not uniform in their level of immune deficiency. Indeed, seven of the patients had CD4 counts below 200/mm', itself a poor prognostic factor for those with AIDS malignan~y.~ Nonetheless, several of these patients had unusually long survival even before administration of IL-2, so the role of a daily subcutaneous dose of IL-2 in protecting against progression of malignant disease cannot yet be assessed. Likewise, while it is of interest that none of the patients had evidence for opportunistic infection during 50 months of IL-2 administration, the sample size and time to follow-up are insufficient to draw any firm conclusions other than the administration of IL-2 did not lead to an adverse outcome in the majority of patients treated.
In summary, prolonged administration of daily low-dose IL-2 is well tolerated on an outpatient basis in patients with AIDS malignancy, and can lead to measurable immune modulation in the absence increased viremia or significant clinical toxicity. The activity of this regimen in preventing opportunistic infections or malignant disease progression in patients with low or clinically undetectable tumor burden has yet to be determined, but a phase I1 trial to assess for such activity is currently underway.
